Published 8/31/2026
Baden LR, Shah NS, Liu STH, Cohen J, Moy J, Kumar A, McComsey GA, Chen P, Floris-Moore M, Singer NG, Fernandez I, Slandzicki AJ, Wiley Z, Kadl A, Kaminsky DA, Hsu H, Walker TA, Hope AA, Ostrosky-Zeichner L, Goldman JD, Peluso MJ, Patterson TF, Parthasarathy S, Mullington JM, Bolin P, Jolley SE, Krishnan JA, Castro M, Hodder SL, Pemu P, Chu HY, Risbano MG, Jerath MR, Mylonakis E, Hurt RT, Alicic R, Azad NS, Sala MA, Harkins MS, Parsonnet J, Stafford N, Robinson P, Hussain S, Qiao X, Hawk ST, Lillestol M, Erdmann N, Gebo KA, Sudhindra P, Sassine J, Marshall GD, Chatterjee T, Morse CG, Kedar E, Stringer WW, Frontera JA, Jordan M, Blaskewicz C, Santana JL, Foot RA, Wongtrakool C, McCarthy MW, Mehari A, Amon A, Cohen AK, Jain N, Maughan C, Lindsay D, Olson R, Broderick S, Rowe P, O'Brien SM, Walt DR, Levy BD, Jason LA, Low PA, Shibao CA, Make B, Bateman L, Redline S, Knopman D, Hernandez AF, Nolen TL, Reist C, Berdan L, Whitley R, Zimmerman KO. Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2026 Aug 31. PMID: 42673984.